業績

ページタイトル画像

論文業績 2016-2018

  • 2018
  • 2017
  • 2016

2018

  1. Watanabe Y, Shimizu N, Iwakawa M, Yamaguchi T, Ban N, Kawana H, Saiki A, Sakaida E, Nakaseko C, Matsuura Y, Aotsuka N, Bujo H, Tatsuno I. Successful treatment of rapidly progressive life-threatening esophageal submucosal hematoma in a patient with van der Hoeve syndrome. J Clin Med Res. 2018;10(2):154-157. PMID: 29317961
  2. Harada K, Doki N, Hagino T, Miyawaki S, Ohtake S, Kiyoi H, Miyazaki Y, Fujita H, Usui N, Okumura H, Miyamura K, Nakaseko C, Fujieda A, Nagai T, Yamane T, Sakamaki H, Ohnishi K, Naoe T, Ohno R, Ohashi K. Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201. Ann Hematol. 2018 Jan;97(1):73-81. PMID: 29196987
  3. Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, Takano H, Kouzai Y, Murase T, Matsue K, Morita S, Sakamoto J, Wakita H, Sakamaki H, Inokuchi K; Kanto CML and Shimousa Hematology Study Groups. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 2018 Jan;109(1):182-192. PMID: 29058817
  4. Iriyama N, Ohashi K, Hashino S, Kimura S, Nakaseko C, Takano H, Koh K, Uchiyama M, Morita S, Sakamoto J, Sakamaki H, Inokuchi K. The efficacy of reduced-dose dasatinib as a subsequent therapy in patients with chronic myeloid leukemia in the chronic phase: The LD-CML Study of the Kanto CML Study Group. Intern Med. 2018;57(1):17-23. PMID: 29033428
  5. Togasaki E, Shimizu N, Nagao Y, Kawajiri-Manako C, Shimizu R, Oshima-Hasegawa N, Muto T, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Ohwada C, Takeuchi M, Sakaida E, Iseki T, Yoshitomi H, Ohtsuka M, Miyazaki M, Nakaseko C. Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia. Ann Hematol. 2018 Apr;97(4):655-662.　PMID: 29332223
  6. Chika Kawajiri-Manako, Emiko Sakaida, Chikako Ohwada, Toshihiro Miyamoto, Taichi Azuma, Jun Taguchi, Takehiko Mori, Yuichi Hasegawa, Tadakazu Kondo, Toshiaki Yujiri, Makoto Yoshimitsu, Kazunori Imada, Shingo Kurahashi, Kaoru Kahata, Tatsuo Ichinohe, Makoto Hirokawa, Yoshiko Atsuta, Chiaki Nakaseko. The efficacy and long-term outcomes of autologous stem cell transplantation in POEMS syndrome: A nation-wide survey in Japan.  Biol Blood Marrow Transplant. 2018 Feb 1. pii: S1083-8791(18)30042-9. PMID: 29409882
  7. Tachibana T, Kanda J, Machida S, Saito T, Tanaka M, Najima Y, Koyama S, Miyazaki T, Yamamoto E, Takeuchi M, Morita S, Kanda Y, Kanamori H, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302). Int J Hematol. 2018 May;107(5):578-585. PMID: 29305770
  8. Takagi S, Tsukamoto S, Park J, Johnson KE, Kawano Y, Moschetta M, Liu CJ, Mishima Y, Kokubun K, Manier S, Salem KZ, Huynh D, Sacco A, Forward J, Roccaro AM, Battinelli EM, Ghobrial IM. Platelets enhance Multiple Myeloma progression via IL-1β upregulation. Clin Cancer Res. 2018 May 15;24(10):2430-2439. PMID: 29440174
  9. Kuwatsuka Y, Tomizawa D, Kihara R, Nagata Y, Shiba N, Iijima-Yamashita Y, Shimada A, Deguchi T, Miyachi H, Tawa A, Taga T, Kinoshita A, Nakayama H, Kiyokawa N, Saito AM, Koh K, Goto H, Kosaka Y, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Ogawa S, Naoe T, Hayashi Y, Horibe K, Manabe A, Mizutani S, Adachi S, Kiyoi H. Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia. Int J Hematol. 2018 Feb;107(2):201-210. PMID: 29027108
  10. Harada Y, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Onizuka M, Takeshita A, Ishida F, Suzushima H, Ishizawa K, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group JALSG. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study.Leuk Res. 2018;66:20-27. PMID: 29360622
  11. Ohwada C, Sakaida E, Kawajiri-Manako C, Nagao Y, Oshima-Hasegawa N, Togasaki E, Muto T, Tsukamoto S, Mitsukawa S, Takeda Y, Mimura N, Takeuchi M, Shimizu N, Misawa S, Iseki T, Kuwabara S, Nakaseko C. Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. Blood. 2018 May 10;131(19):2173-2176. PMID: 29599110
  12. Takaishi K, Muto T, Mimura N, Takiguchi J, Nagao Y, Oshima-Hasegawa N, Tsukamoto S, Takeda Y, Mitsukawa S, Takeuchi M, Ohwada C, Ota S, Iseki T, Nakaseko C, Sakaida E. Long-term complete remission following tandem autologous stem cell transplantation and consolidative radiotherapy for refractory mediastinal gray-zone lymphoma. Int J Hematol. 2018 May 21. [Epub ahead of print] PMID: 29786758
  13. Kawano Y, Zavidij O, Park J, Moschetta M, Kokubun K, Mouhieddine TH, Manier S, Mishima Y, Murakami N, Bustoros M, Pistofidis RS, Reidy M, Shen YJ, Rahmat M, Lukyanchykov P, Karreci ES, Tsukamoto S, Shi J, Takagi S, Huynh D, Sacco A, Tai YT, Chesi M, Bergsagel PL, Roccaro AM, Azzi J, Ghobrial IM. Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. J Clin Invest. 2018 Jun 1;128(6):2487-2499. PMID: 29558366

 

和文論文

  1. 中世古知昭 多発性骨髄腫に対するVRd療法：Rd療法との比較と自家移植の意義．特集：造血障害とその類縁疾患―最近展開　血液内科 2018; 76(1): 101-105
  2. 中世古知昭，堺田惠美子．特集：ヘマトネフロロジー：血液・凝固疾患と腎障害，テーマ：3. 腎沈着症　POEMS症候群 (Crow-Fukase症候群)　腎と透析 2018 in press
  3. 三村尚也，井関徹. 第3章遺伝子関連検査関連事項. 2-(1) 体細胞遺伝子検査　②血液疾患　ここが知りたい遺伝子診療はてなBOOK. 中外医学社 2018 page115-117（単行本）

2017

  1. Muto T, Ohwada C, Takaishi K, Isshiki Y, Nagao Y, Hasegawa N, Kawajiri-Manako C, Togasaki E, Shimizu R, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Takeuchi M, Sakaida E, Misawa S, Shimizu N, Iseki T, Kuwabara S, Nakaseko C. Safety and efficacy of granulocyte-colony stimulating factor monotherapy for peripheral blood stem cell collection in POEMS Syndrome. Biol Blood Marrow Transplant 2017;23(2):361-3, PMID: 27840209
  2. Konuma T, Kondo T, Yamashita T, Uchida N, Fukuda T, Ozawa Y, Ohashi K, Ogawa H, Kato C, Takahashi S, Kanamori H, Eto T, Nakaseko C, Kohno A, Ichinohe T, Atsuta Y, Takami A, Yano S. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8. Ann Hematol 2017; 96(3): 469-78, PMID: 28058493
  3. Ishizawa K, Fukuhara N, Nakaseko C, Chiba S, Ogura M, Okamoto A, Sunaga Y, Tobinai K. Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Jpn J Clin Oncol 2017;47(1):54-60. PMID: 28122892
  4. Shimizu R, Ohwada C, Nagao Y, Togasaki E, Kawajiri C, Muto T, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Takeuchi M, Sakaida E, Iseki T, Nakaseko C. The successful treatment of a cord blood transplant recipient with Varicella Zoster virus meningitis, radiculitis and myelitis with foscarnet. Intern Med. 2017;56(3):353-6., PMID: 28154282
  5. Takahashi K, Suzuki E, Yokoyama M, Inoue M, Wakamatsu T, Saito T, Kusakabe Y, Ogasawara S, Ooka Y, Tawada A, Nagao Y, Nakaseko C, Chiba T. Successful treatment of hepatocellular carcinoma complicated by Fanconi anemia. Case Rep Gastroenterol. 2017;11(1):29-35. PMID: 28203135
  6. Sakaida E, Ebata T, Iwasawa S, Kurimoto R, Yonemori S, Ota S, Nakatani Y, Sekine I, Takiguchi Y. Potential activity of amrubicin as a salvage therapy for Merkel cell carcinoma - a case report. Int Med 2017;56(5):567-70., PMID: 28250307
  7. Hasegawa N, Oshima M, Sashida G, Matsui H, Koide S, Saraya A, Wang C, Muto T, Takane K, Kaneda A, Shimoda K, Nakaseko C, Yokote K, Iwama A. Impact of combinatorial dysfunctions in epigenetic regulators Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome. Leukemia 2017; 31(4):861-71. PMID: 27694924
  8. Togasaki E, Takeda J, Yoshida K, Shiozawa Y, Takeuchi M, Oshima M, Saraya A, Iwama A, Yokote K, Sakaida E, Hirase C, Takeshita A, Imai K, Okumura H, Morishita Y, Usui N, Takahashi N, Fujisawa S, Shiraishi Y, K Chiba K, Tanaka H, Kiyoi H, Ohnishi K, Ohtake S, Asou N, Kobayashi Y, Miyazaki Y, Miyano S, Ogawa S, Matsumura I, Nakaseko C, Naoe T for the Japan Adult Leukemia Study Group (JALSG). Frequent somatic mutations in epigenetic regulators in newly-diagnosed chronic myeloid leukemia. Blood Cancer J 2017 7, e559; doi:10.1038/bcj.2017.36
  9. Shimizu N, Tanaka S, Watanabe Y, Tokuyama W, Hiruta N, Ohwada C, Sakaida E, Nakaseko C, Tatsuno I. Syndrome of Inappropriate Antidiuretic Hormone Secretion in a Patient with Mucosa-associated Lymphoid Tissue Lymphoma. Intern Med. 2017;56(23):3225-3229., PMID: 29021471
  10. Doki N, Kakihana K, Ashizawa M, Onoda M, Ohwada C, Kobayashi S, Gotoh M, Fujisawa S, Okamoto S, for the Kanto Study Group for Cell Therapy. Clinical characteristics of calcineurin inhibitor-induced pain syndrome (CIPS) after allogeneic hematopoietic stem cell transplantation. J Hematopoietic Cell Transplant 2017; 6(2): 115-119
  11. Naoya Mimura.Novel therapeutic approaches to achieve the cure of multiple myeloma. Chiba Medical J. 2017; 93E:17-23.
  12. Isshiki Y, Ohwada C, Sakaida E, Onoda M, Aotsuka N, Tanaka H, Fukazawa M, Cho R, Sugawara T, Kawaguchi T, Hara S, Yokota A.  CD20 positivity and white blood cell count predict treatment outcomes in Philadelphia chromosome-negative acute lymphoblastic leukemia patients ineligible for pediatric-inspired chemotherapy. Jpn J Clin Oncol. 2017;47(11):1047-1054.PMID:28973362
  13. Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I, Matsuda A, Aoki M, Ito K, Shibayama H. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol. 2017 Oct 26. PMID:29076005
  14. Rizq O, Mimura N, Oshima M, Saraya A, Koide S, Kato Y, Aoyama K, Nakajima-Takagi Y, Wang C, Chiba T, Ma A, Jin J, Iseki T, Nakaseko C, Iwama A. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition. Clin Cancer Res. 2017 Aug 15;23(16):4817-4830. PMID:28490465
  15. Takahashi N, Nakaseko C, Kobayashi Y, Miyamura K, Ono C, Koide Y, Fujii Y, Ohnishi K. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment. Int J Hematol. 2017 Sep;106(3):398-410., PMID:28409328
  16. Hideshima T, Cottini F, Nozawa Y, Seo HS, Ohguchi H, Samur MK, Cirstea D, Mimura N, Iwasawa Y, Richardson PG, Munshi NC, Chauhan D, Massefski W, Utsugi T, Dhe-Paganon S, Anderson KC. p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 Mar 9;129(10):1308-1319. doi: 10.1182/blood-2016-09-738500. Epub 2017 Jan 12. PMID: 28082445
  17. Yokoyama M, Chiba T, Zen Y, Oshima M, Kusakabe Y, Noguchi Y, Yuki K, Koide S, Tara S, Saraya A, Aoyama K, Mimura N, Miyagi S, Inoue M, Wakamatsu T, Saito T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Otsuka M, Miyazaki M, Yokosuka O, Iwama A. Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma. Oncotarget. 2017 Mar 28;8(13):21315-21326. doi: 10.18632/oncotarget.15528. PMID: 28423509
  18. Hideshima T, Mazitschek R, Qi J, Mimura N, Tseng JC, Kung AL, Bradner JE, Anderson KC. HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.　Oncotarget. 2017 Jul 5;8(46):80109-80123. doi: 10.18632/oncotarget.19019. eCollection 2017 Oct 6. PMID: 29113288

 

和文論文

  1. 大和田千桂子，中世古知昭.　III-23 造血系・リンパ系疾患　原発性マクログロブリン血症．血液疾患　最新の治療2017-2019　編集：小澤敬也，中尾眞二，松村到，p213-216, 南江堂，東京，2017（単行本）
  2. 三村尚也　骨髄腫治療を理解するためのMyeloma Biology　2.骨髄腫の進行をもたらす骨髄腫細胞の分子病態　2)　エピジェノム　（１）メチル化、脱メチル化　多発性骨髄腫Updating　第10巻, 医薬ジャーナル社, 2017 page 48-57　（単行本）
  3. 三村尚也，中世古知昭　第2章　各種治療薬の使い方・考え方 7. パノビノスタット 多発性骨髄腫　新規治療薬の使い方・考え方，編集:石田禎夫, 先端医学社, 2017 page 124-133 (単行本)
  4. 三村尚也ほか（日本語版翻訳）　IMF Concise Review of the Disease and Treatment Options 2015 Edition, International Myeloma Foundation. 日本語版 2017 in press           （単行本）
  5. 武内正博，中世古知昭．２．新しい多発性骨髄腫の治療指針に基づく骨髄腫治療戦略，1)移植適応骨髄腫の治療指針．特集　多発性骨髄腫の臨床　～現状と展望～　血液フロンティア　2017; 27(1):31-39
  6. 中世古知昭．慢性骨髄性白血病の治療の進歩．特集「白血病診療の実際－最新の診断と治療」　日本医師会雑誌　2017; 145(12): 2579-83
  7. 高橋直人，川口辰哉，中世古知昭，西脇嘉一．慢性骨髄性白血病薬物療法の長期安全性 ―ボスチニブのテータから考える― LEUKEMIA INSIGHT 2017; 5: 2-5
  8. 高石浩司，堺田惠美子，中世古知昭．POEMS症候群の診断と治療．血液内科 74巻：第2号：232
  9. 前田隆宏, 大岡美彦, 横山昌幸, 若松徹, 井上将法, 齊藤朋子, 日下部裕子, 小笠原定久, 鈴木英一郎, 太和田暁之, 三村尚也, 堺田恵美子, 中世古知昭, 岸本充, 千葉哲博. 急性前骨髄球性白血病を併発した肝細胞癌の1例．肝臓　2017; 58(3): 176-82
  10. 清水直美，吉田正，松澤康雄，渡邉康弘，蛭田啓之，中世古知昭，龍野一郎．der(1;7)(q10;p10)を含む複雑染色体核型を呈した骨髄異形成症候群併存下での肺神経内分泌大細胞癌治療の経験．臨床病理 2017 in press
  11. 酒井紫緒，三村尚也，立花美智子，日野もえ子，竹田勇輔，武内正博，大和田千桂子，堺田惠美子，中世古知昭，井関徹．輸血・細胞療法部における同種造血幹細胞移植ドナー外来の有効性と意義．日本輸血・細胞治療学会誌　2017 in press
  12. 中世古知昭．慢性骨髄性白血病の病態解明と分子標的治療．「特集：白血病・病態解明と分子標的治療」　Medical Science Digest 2017; 43(8): 24-27
  13. 中世古知昭，大和田千桂子，堺田惠美子．骨髄腫類縁疾患の診断と治療．ALアミロイドーシス，POEMS症候群の診断と治療．「特集：慢性疾患となった骨髄腫 どのように診断するか？どのように付き合っていくか？」 内科 2017; 120(4): 949-954
  14. 中世古知昭．慢性骨髄性白血病の標準治療とポナチニブ．「特集：血液腫瘍の最近のトピック」　腫瘍内科 2017; 20(5): 381-388

2016

  1. Kanda Y, Kobayashi T, Mori T, Tanaka M, Nakaseko C, Yokota A, Watanabe R, Kako S, Kakihana K, Kato J, Tanihara A, Doki N, Ashizawa M, Kimura SI, Kikuchi M, Kanamori H, Okamoto S. A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation. Bone Marrow Transplant. 2016; 51(1):103-9. PMID: 26437063
  2. Muto T, Ohwada C, Yamazaki A, Sugita S, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Takeuchi M, Sakaida E, Iseki T, Shimizu N, Morio T, Nakaseko C. Long-term complete remission by infusion of ex vivo-expanded donor-derived CD4+ lymphocytes for an early relapse of Hodgkin lymphoma after cord blood transplantation. Leuk Lymphoma 2016; 57(1): 230-2. PMID: 25962436.
  3. Muto T, Takeda Y, Tsukamoto S, Sakai S, Mimura N, Ohwada C, Takeuchi M, Sakaida E, Ota S, Iseki T, Shimizu N, Morio T, Nakaseko C. Successful treatment of cytomegalovirus enteritis after unrelated allogeneic stem cell transplantation by the infusion of ex vivo-expanded CD4+ lymphocytes derived from the recipient’s peripheral blood donor cells. Transpalnt Infect Dis 2016;18(1):93-7.　PMID: 26613364
  4. Muto T, Ohwada C, Sawai S, Beppu M, Tsukamoto S, Takeda Y, Mimura N, Takeuchi M, Sakaida E, Sogawa K, Misawa S, Shimizu N, Iseki T, Nomura F, Kuwabara S, Nakaseko C. Acutely deteriorated extravascular volume overload during peripheral blood stem cell mobilization in POEMS syndrome: A case series with cytokine analysis. Transfus Apher Sci 2016; 54(2): 276-81. PMID: 26586169
  5. Oshima M, Hasegawa N, Mochizuki-Kashio M, Muto T, Miyagi S, Koide S, Yabata S, Wendt GR, Saraya A, Wang C, Shimoda K, Suzuki Y, Iwama A. Ezh2 regulates the Lin28/let-7 pathway to restrict activation of fetal gene signature in adult hematopoietic stem cells. Exp Hematol. 2016; 44(4): 282-296. PMID: 26773568
  6. Yakushijin K, Atsuta Y, Doki N, Yokota A, Kanamori H, Miyamoto T, Ohwada C,  Miyamura K, Nawa Y, Kurokawa M, Mizuno I, Mori T, Onizuka M, Taguchi J, Ichinohe T, Yabe H, Morishima Y, Kato K, Suzuki R, Fukuda T. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcomes. Bone Marrow Transplant. 2016; 51(3): 403-9. PMID: 26595082
  7. Isshiki Y, Ono K, Shono K, Onoda M, Yokota A. Autoimmune Thyroid Dysfunction after Allogeneic Hematopoietic Stem Cell Transplantation. Leuk Lymphoma. 2016; 57(5):1227-9. PMID: 26308103
  8. Sakaida E, Iwasawa S, Kurimoto R, Ebata T, Imai C, Oku T, Sekine I, Tada Y, Tatsumi K, Takiguchi Y. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study. Jpn J Clin Oncol. 2016: 46(4):370-377 PMID: 26755829
  9. Ohguchi H, Hideshima T, Bhasin MK, Gorgun GT, Santo L, Cea M, Samur MK, Mimura N, 　Suzuki R, Tai YT, Carrasco RD, Raje N, Richardson PG, Munshi NC, Harigae H, Sanda T, Sakai J, Anderson KC. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun. 2016 Jan 5;7:10258. PMID: 26728187
  10. Kato M, Yamashita T, Suzuki R, Matsumoto K, Nishimori H, Takahashi S, Iwato K, Nakaseko C, Kondo T, Imada K, Kimura F, Ichinohe I, Hashii Y, Kato K, Atsuta A, Taniguchi S, Fukuda T. Donor cell-derived hematologic malignancy: a survey by the Japan Society for Hematopoietic Cell Transplantation. Leukemia 2016;30(8):1742-5. PMID: 26867671
  11. Kozuki T, Nogami N, Kitajima H, Iwasawa S, Sakaida E, Takiguchi Y, Ikeda S, Yoshida M, Kato T, Miyamoto S, Sakamaki K, Shinkai T, Watanabe K. Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent non-small cell lung cancer in elderly patients: TORG1015. BMC Cancer. 2016; 16:306. PMID: 27177035
  12. Sarah Jarvis, Gunnar Birgegård, Tamara Lado Cives, Sélim Aractingi, Chiaki Nakaseko, Claire Harrison, Melania Moreno Vega, Jean‑Jacques Kiladjian, Salah Alimam, Manuel Martinez‑Sellés Advancing our clinical perspective in haematology: what is your approach? Summary of presentations from the 11th New Horizons in Haematology conference which took place on 11th March 2016 and was webcast live to moderated audiences in Hong Kong, Italy, Japan, Russia, South Africa, and Spain, and to individuals throughout the world. Eur Med J Haematol Supplement 2016 June, 1-9
  13. Shimizu R, Muto T, Aoyama K, Choi K, Takeuchi M, Koide S, Hasegawa N, Isshiki Y, Togasaki E, Kawajiri C, Nagao Y, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Ohwada C, Sakaida E, Iseki T, Starczynowski DT, Iwama A, Yokote K, Nakaseko C. Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia. Leuk Res 2016; 50: 85-94, PMID: 27697661
  14. Sugita Y, Ohwada C, Kawaguchi T, Muto T, Tsukamoto S, Takeda Y, Mimura N, Takeuchi M, Sakaida E, Shimizu N, Tanaka H, Abe D, Fukazawa F, Sugawara T, Aotsuka N, Nishiwaki K, Shono K, Ebinuma H, Fujimura K, Bujo H, Yokote K, Nakaseko C. Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-Cell lymphoma: a multicenter prospective analysis. Clin Chim Acta 2016; 463: 47-52, PMID: 27725222
  15. Hideshima T, Qi J, Paranal RM, Tang W, Greenberg E, West N, Colling ME, Estiu G, Mazitschek R, Perry JA, Ohguchi H, Cottini F, Mimura N, Görgün G, Tai YT, Richardson PG, Carrasco RD, Wiest O, Schreiber SL, Anderson KC, Bradner JE. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A. 2016; 113(46): 13162-7., PMID: 27799547
  16. Asano T, Matsuoka KI, Iyama S, Ohashi K, Inamoto Y, Ohwada C, Murata M, Satake A, Yoshida C, Nakase K, Mori Y, Tanimoto M. Phase I/IIa Study of Low Dose Subcutaneous Interleukin-2 (IL-2) for Treatment of Refractory Chronic Graft Versus Host Disease. Acta Med Okayama. 2016;70(5):429-33., PMID: 27777442

 

和文論文

  1. 大和田千桂子，中世古知昭.　日本臨牀増刊号　多発性骨髄腫学―最新の診療と基礎研究―　第VIII章. 特殊病型と類縁疾患の診断と治療　6. POEMS症候群.　p535-539, 日本臨牀社，大阪，2016（単行本） ISSN 0047-1852
  2. 長谷川渚，堺田恵美子，中世古知昭．日本臨牀2016年12月増刊号　白血病学（下）―最新の基礎，臨床研究―．第Ⅷ章　白血病の治療：各論（化学療法と分子標的療法），12. 移行期・急性転化期の慢性骨髄性白血病，p167-71，編集：谷脇雅史，2016（単行本）
  3. 武内正博，中世古知昭．診断と治療のABC 113 慢性骨髄性白血病・骨髄増殖性腫瘍 第3章　診断，3. その他の骨髄増殖性腫瘍の診断, 企画：木村文彦，最新医学社，大阪，p85-91, 2016（単行本）
  4. 大和田千桂子.　血液科研修ノート 第１章　血液科研修でのアドバイス　A. 血液科医になる人へ　3. ワークライフバランスを考える～血液内科を生涯のプロフェッショナルとするために　　監修：永井良三，編集：神田善伸，p356-9，診断と治療社，東京，2016（単行本）
  5. 中世古知昭.　血液科研修ノート　第5章　血液疾患の診療，　C. 白血球系疾患：脾腫陽性疾患，3. 血球貪食症候群　監修：永井良三，編集：神田善伸，p，診断と治療社，東京，2016（単行本）
  6. 中世古知昭. ＩＩ．臨床編 b 移植合併症　9.非感染性呼吸器合併症 みんなに役立つ造血幹細胞移植の基礎と臨床改訂 神田善伸編　医薬ジャーナル社，大阪，2016; p530-537（単行本） ISBN978-4-7532-2810-0
  7. 松井愼一郎, 竹田勇輔, 一色佑介, 山崎敦子，中尾三四郎，高石浩司, 永尾侑平, 長谷川渚, 東ヶ崎絵美, 清水亮, 川尻千華，酒井紫緒, 三村尚也, 武内正博, 大和田千桂子, 堺田恵美子，井関徹, 今留謙一，中世古知昭. 著明な心嚢水貯留を主症状として発症し，同種末梢血幹細胞移植が奏効した慢性活動性EBウイルス感染症. 臨床血液 2016; 57(5):624-629. PMID: 27263789
  8. 木村賢司，武内正博，長谷川渚, 東ヶ崎絵美, 清水亮, 川尻千華，武藤朋也，塚本祥吉, 竹田勇輔，大和田千桂子，堺田惠美子，酒井紫緒，三村尚也，太田聡，井関徹，中世古知昭．All-trans retinoic acid単独投与後に重度の口内炎と回盲部腸管穿孔を発症したHLA-B51陽性急性前骨髄球性白血病．臨床血液　2016;57(6):765-70. PMID: 27384858
  9. 中世古知昭.　私のこの一枚：30年以上の経過を有し，高度の形質細胞肺浸潤を伴った多中心性Castleman病の一例　血液フロンティア　2016; 26(7): 3-7
  10. 長谷川渚，堺田惠美子，中世古知昭．ボスチニブとCML. 特集／血液腫瘍の最近のトピックス－新たに保険承認されたありは適応拡大された造血器腫瘍に対する薬剤．腫瘍内科　2016; 17(6): 599-604
  11. 三村尚也, 岩間厚志.　多発性骨髄腫におけるエピジェネティック異常  日本臨牀2016年5月増刊号　多発性骨髄腫学-最新の診療と基礎研究-　 2016; 74(5): 163-167.
  12. 高橋直人，中世古知昭，川口辰哉，西脇嘉一.　慢性骨髄性白血病の長期安全性－ボスチニブのデータから考える　Leukemia Insight in press
  13. 堺田惠美子. 悪性腫瘍の病態と治療 SBO　105　悪性腫瘍の治療における薬物治療の位置づけ.　日本薬学会スタンダード薬学シリーズ　総監修 市川厚 第6巻　薬と疾病　Ⅲ.　薬物治療(2)および薬物治療に役だつ情報　第3版　東京化学同人　2016年12月　in press
  14. 中世古知昭.　多発性骨髄腫に対する造血幹細胞移植　日本内科学会雑誌　2016; 105(7):1246-1254
  15. 酒井紫緒.　造血幹細胞採取の実際　平成28年度HCTC認定講習テキスト 2016 p11-17，p5-9，JSHCT monograph Vol.43 一般社団法人日本造血細胞移植学会，名古屋，2016，ISSN1344-5898（単行本）
  16. 川尻千華，中世古知昭．POEMS症候群〜いかに考え、治療するか〜．Pharma Medica 2016; 34(1):75-79.
  17. 前田隆宏，千葉哲博，大岡美彦，横山昌幸，若松徹，井上将法，日下部裕子，齋藤朋子，小笠原定久，鈴木英一郎，太和田暁之，堺田恵美子，中世古知昭，井関徹，岸本充，横須賀收．再生不良性貧血による高度な汎血球減少を伴った肝細胞癌に対して治療介入を行った2例．肝臓 2016; 57(10): 557-560.